| goserelin acetate / Generic mfg. |
NCT00536653: Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer |
|
|
| Completed | N/A | 618 | Europe | Bicalutamide and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate) | Wirral University Teaching Hospital NHS Trust | Osteoporosis | | 01/07 | | |
NCT00540059: Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial |
|
|
| Completed | N/A | 1950 | Europe | | AstraZeneca | Prostate Carcinoma | | | | |
CHAMPION, NCT00523484: Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts |
|
|
| Completed | N/A | 1200 | RoW | | AstraZeneca | Prostate Cancer | 11/08 | | | |
AZTEK EXT, NCT00692874: Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy |
|
|
| Completed | N/A | 1646 | Europe | | AstraZeneca | Prostate Cancer | 07/10 | 09/10 | | |
NCT01120262: S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin |
|
|
| Completed | N/A | 545 | US | gene expression analysis, polymorphism analysis, laboratory biomarker analysis | Southwest Oncology Group, National Cancer Institute (NCI) | Prostate Cancer | 07/10 | 07/10 | | |
| Completed | N/A | 1376 | Europe | | AstraZeneca | Prostate Cancer, Obesity | 03/13 | 03/13 | | |
